Tau, anti-inflammation and orals form Biogen's future Alzheimer's pipeline

“What does it mean to be a leader in Alzheimer’s disease?”

That’s the question Biogen is asking itself, and the question many of the company’s peers are working fervently to answer as the heated race to differentiate from the first batch of Alzheimer’s treatments turns to a simmer.